Cancer researchers in Melbourne have discovered that a new class of anti-cancer agents may be effective in treating multiple myeloma.
The research revealed that the majority of myelomas rely on a protein called MCL-1 to stay alive. Potential drugs that inhibit MCL-1 are in pre-clinical development and may become a promising new treatment for multiple myeloma.
Each year more than 1,700 Australians are diagnosed with multiple myeloma, which is a cancer of immune cells called plasma cells. Currently, the treatments are only able to halt the progression of the disease and relieve symptoms, but cannot cure the disease.
Researchers at Walter and Eliza Hall Institute (WEHI), Australian Centre for Blood Diseases, Monash University and the Alfred Hospital investigated the ‘survival proteins’ that keep myeloma cells alive, allowing the cancer to persist.
The survival of many cancer types relies on a family of related survival proteins called BCL-2 family proteins, Professor David Huang at WEHI said.
“In the past decade there has been considerable interest in the using anti-cancer agents called ‘BH3-mimetics’ to kill cancer cells by blocking the BCL-2 family proteins.”
“Recent clinical trials have demonstrated that a BH3-mimetic that switches off the protein BCL-2 is an effective treatment for certain forms of leukaemia.”
“Our latest research has focused on which BH3-mimetics would be the most effective in treating multiple myeloma, a cancer for which new treatments are urgently needed,” Professor Huang said.
Dr Jianan Gong at WEHI said the team discovered that the majority of myeloma samples died when MCL-1 was switched off.
“In contrast, only around one-quarter were susceptible to inhibiting BCL-2. This finding is in keeping with earlier research at the Walter and Eliza Hall Institute that pinpointed MCL-1 as the likely protein that keeps myeloma cells alive.”
“Our research shows that switching off MCL-1 has the potential to be effective new treatment approach for the majority of patients with myeloma,” Dr Gong said.
Professor Andrew Roberts at WEHI said that there had been considerable interest in developing anti-cancer agents that target MCL-1.
“As yet, these inhibitors are still in pre-clinical development,” he said.
“Our results suggest that, once necessary laboratory testing for safety is completed, clinical trials of their effectiveness in treating patients with multiple myeloma that is no longer responding to current therapies would be well justified.”
The Australian Cancer Research Foundation has supported WEHI by providing three grants, totalling AUD $5.5million, towards cutting edge cancer research equipment and technology.
The research was published in the journal Blood. The original news article was posted on the WEHI website. Image courtesy of WEHI, (L-R) Professor David Huang, Dr Jianan Gong, Dr David Segal, Ms Yuan Yao and Professor Andrew Roberts.